Genmab To Discontinue Clinical Development Of Acasunlimab To Focus On Priority Programs
Kort samengevat
BRUSSELS (dpa-AFX) - Genmab A/S (GMAB), Monday announced the decision to discontinue further clinical development of acasunlimab to focus on programs with the highest potential impact, such as
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij FinanzNachrichten.de.
Lees het volledige bericht ↗